1. Scrip
  2. >>R&D

Oyster Point Looks To Compete In Dry Eye With Nasal Spray Therapeutic

 
• By Joseph Haas

Spun out from Oculeve in tandem with that company’s acquisition by Allergan, Oyster Point hopes to develop a nasal spray that can address the underlying cause of dry eye. It has two candidates on parallel courses in Phase II with a goal of choosing one to advance into Phase III.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes

Privately held Oyster Point Pharma Inc. has unveiled positive data from a dose-ranging Phase IIb trial of one of its two candidates for dry eye, in each case a nasal spray candidate that agonizes the nicotinic acetylcholine receptor (nAChR) pathway. OC-02 met primary endpoints of both signs and symptoms of dry eye disease in the data disclosed on July 12, while OC-01 continues in Phase II development.

Spun out from Oculeve Inc. in tandem with that firm’s 2015 acquisition by Allergan PLC, Oyster Point’s candidates represent an effort to treat dry eye with a therapeutic similar to the way Oculeve/Allergan’s True Tear device, an intranasal neurostimulator, addresses the disease. (Also see "Beyond Restasis: Allergan buys Oculeve dry eye device" - Scrip, 7 July, 2015.) True Tear obtained US FDA approval in May 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.